Market closed

Actinium Pharmaceuticals/$ATNM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Actinium Pharmaceuticals

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Ticker

$ATNM
Sector
Health Care

Trading on

AMEX

Industry

Biotechnology
Headquarters
New York, United States

Employees

37
Website
www.actiniumpharma.com

ATNM Metrics

BasicAdvanced
$39M
-
-$1.40
0.13
-

$39M

0.13

$10.24

$1.10

359K

10.254

10.143

3.012

4.478

-32.85%

-100.05%

453.074

1.03

1.03

-1.054

-26.82%

-58.35%

4.91%

What the Analysts think about ATNM

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Actinium Pharmaceuticals stock.

ATNM Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ATNM Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ATNM News

AllArticlesVideos
My Top 2 Stock Picks For A 2025 Rebound

My Top 2 Stock Picks For A 2025 Rebound

Seeking Alpha·1 month ago
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

The Schall Law Firm Encourages Investor Participation In An Inquiry Into Actinium Pharmaceuticals Inc For Securities Fraud

Accesswire·2 months ago
Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Actinium Pharmaceuticals, Inc. Is Being Investigated For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm

Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ATNM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Actinium Pharmaceuticals stock?

Actinium Pharmaceuticals (ATNM) has a market cap of $39M as of January 15, 2025.

What is the P/E ratio for Actinium Pharmaceuticals stock?

The price to earnings (P/E) ratio for Actinium Pharmaceuticals (ATNM) stock is 0 as of January 15, 2025.

Does Actinium Pharmaceuticals stock pay dividends?

No, Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Actinium Pharmaceuticals dividend payment date?

Actinium Pharmaceuticals (ATNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Actinium Pharmaceuticals?

Actinium Pharmaceuticals (ATNM) has a beta rating of 0.13. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.